Distribution of naloxone, traditionally through community-based naloxone programs, is a component of a comprehensive strategy to address the epidemic of prescription opioid and heroin overdose deaths in the United States. Recently, there has been increased focus on naloxone prescription in the outpatient setting, particularly through retail pharmacies, yet data on this practice are sparse. We found an 1170% increase in naloxone dispensing from US retail pharmacies between the fourth quarter of 2013 and the second quarter of 2015. These findings suggest that prescribing naloxone in the outpatient setting complements traditional community-based naloxone programs. (Am J Public Health. 2016;106: 689-690.
O
verdose deaths from prescription opioids and heroin constitute a public health crisis in the United States. Distribution of naloxone to individuals likely to witness an overdose is a key component of a comprehensive strategy to address the opioid epidemic 1 and traditionally has occurred through community-based naloxone programs. 2 Distribution of naloxone has been shown to reduce overdose deaths in communities that implemented overdose education and naloxone distribution programs. 3 Recently, there has been increased focus on expanding naloxone access through prescription of naloxone in the outpatient setting. 4, 5 Although data on community-based naloxone programs are available and suggest continued growth in the number of programs and the number of people receiving naloxone from these programs, 2 a paucity of information is available on outpatient naloxone prescribing to those using opioids (illicitly or by prescription), their caregivers, or their family members. To inform efforts to comprehensively expand naloxone access, we analyzed national prescription trends.
METHODS
Prescription data are from IMS Health's National Prescription Audit, which estimates prescriptions from US pharmacies based on a proprietary sample that includes approximately 67% of the pharmacies in the United States and captures nearly 80% of dispensed retail prescriptions. 6 We calculated quarterly counts of naloxone prescriptions dispensed by US retail pharmacies between July 2010 and June 2015, stratified into 3 groups: (1) Evzio, an auto-injector approved in 2014; (2) the 2 milligram/2 milliliter formulation typically used off label with a nasal atomizer in community settings 2 ; and (3) other formulations. We also calculated the percentage of dispensed naloxone by recipient gender and age and provider specialty for the 12-month period ending June 2015.
RESULTS
Naloxone dispensing from US retail pharmacies was low and stable between the third quarter of 2010 and the fourth quarter of 2013, ranging between 241 and 463 prescriptions per quarter. Starting with the first quarter of 2014, there was a steep rise in naloxone dispensing (Figure 1 
Between July 2014 and June 2015, 50.7% of the naloxone prescriptions were dispensed to females, and 45.6% were dispensed to males (unspecified = 3.6%). Those aged 19 years and younger accounted for 4.3% of the prescriptions, those aged 20 to 39 years accounted for 28.7%, those aged 40 to 59 years accounted for 42.7%, those aged 60 to 74 years accounted for 17.1%, and those aged 75 years and older accounted for 5.6% (unspecified = 1.6%). Primary care physicians accounted for 35.1% of the prescriptions, followed by nurse practitioners and physician assistants (19.3%), pain medicine specialists (10.0%), addiction medicine specialists or psychiatrists (6.1%), and physical medicine and rehabilitation physicians or occupational medicine specialists (5.0%); all other specialties combined accounted for 24.5%.
between the fourth quarter of 2013 and the second quarter of 2015. This increase occurred alongside a 187% increase in the number of naloxone kits distributed by community-based organizations and a 160% increase in the number of reversals reported by these organizations between 2010 and 2014. 2 The introduction of Evzio, a product designed for use by nonmedical personnel, appears to have supplemented the dispensing of other naloxone products.
Most naloxone in the community continues to be distributed through community-based programs, primarily to illicit drug users. However, challenges to sustaining such programs, difficulty in ensuring optimal geographic representation, and the magnitude of the opioid crisis require additional methods of dissemination. Our findings suggest that the rapid growth of naloxone prescriptions in the outpatient setting can be a complementary approach. The finding that primary care physicians accounted for the largest percentage of naloxone prescriptions is consistent with previous research indicating that these providers prescribe most opioids. 7 Overall, we must address the multiple barriers to naloxone prescription, including stigma of addressing health issues related to addiction, limited knowledge about naloxone prescribing, uncertainty about who should receive naloxone, and concerns about naloxone availability and cost. 8 Future research should examine the facilitators of and barriers to naloxone prescription across medical specialties as well as the relation between increased naloxone prescribing and mortality. CONTRIBUTORS C. M. Jones conceptualized the brief, was responsible for the data analyses, and was the lead writer. P. G. Lurie and W. M. Compton conceptualized the brief, contributed specific content, and drafted revisions of the brief.
